Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-003834-34
    Sponsor's Protocol Code Number:NBI-1065844-CIAS2023
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2023-01-16
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-003834-34
    A.3Full title of the trial
    A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment
    Estudio aleatorizado, doble ciego, comparativo con placebo y de grupos paralelos para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia, seguido de un tratamiento abierto
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia
    Estudio para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia
    A.3.2Name or abbreviated title of the trial where available
    ERUDITE Study
    Estudio ERUDITE
    A.4.1Sponsor's protocol code numberNBI-1065844-CIAS2023
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05182476
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNeurocrine Biosciences, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNeurocrine Biosciences, Inc.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNeurocrine Biosciences, Inc.
    B.5.2Functional name of contact pointMedical Information Call Center
    B.5.3 Address:
    B.5.3.1Street Address12780 El Camino Real
    B.5.3.2Town/ citySan Diego
    B.5.3.3Post codeCA 92130
    B.5.3.4CountryUnited States
    B.5.4Telephone number+34932483137
    B.5.6E-mailmedinfo@neurocrine.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLuvadaxistat
    D.3.2Product code NBI-1065844
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLuvadaxistat
    D.3.9.2Current sponsor codeNBI-1065844
    D.3.9.4EV Substance CodeSUB194910
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLuvadaxistat
    D.3.2Product code NBI-1065844
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLuvadaxistat
    D.3.9.2Current sponsor codeNBI-1065844
    D.3.9.4EV Substance CodeSUB194910
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Cognitive Impairment Associated With Schizophrenia
    Deterioro cognitivo asociado a la esquizofrenia
    E.1.1.1Medical condition in easily understood language
    Cognitive Impairment and Schizophrenia
    Deterioro Cognitivo y Esquizofrenia
    E.1.1.2Therapeutic area Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10039626
    E.1.2Term Schizophrenia
    E.1.2System Organ Class 10037175 - Psychiatric disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in subjects with schizophrenia.
    Evaluar la seguridad y la eficacia de Luvadaxistat en comparación con un placebo en la mejora del rendimiento cognitivo en participantes con esquizofrenia.
    E.2.2Secondary objectives of the trial
    To evaluate the efficacy of luvadaxistat compared with placebo on improving cognitive function in subjects with schizophrenia.
    Evaluar la eficacia de Luvadaxistat en comparación con un placebo en la mejora del rendimiento cognitivo en participantes con esquizofrenia.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Completed written informed consent
    2. Subject must be 18 to 50 years of age (inclusive) and able to comply with all protocol procedures.
    3. Diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
    4. The initial diagnosis of schizophrenia must be ≥1 year before screening.
    5. The subject is currently receiving a stable regimen of psychotropic medications
    6. Subject has stable symptomatology ≥3 months before the screening visit.
    7. The subject must have an adult informant.
    8. A body weight of at least 45 kg and a body mass index (BMI) of 18.0 to 45.0 kg/m2, inclusive.
    1. Haber cumplimentado el consentimiento informado por escrito.
    2. El participante debe tener entre 18 y 50 años de edad (incluído) para cumplir con todos los procedimientos del protocolo.
    3. Diagnóstico de esquizofrenia según la definición del Manual diagnóstico y estadístico de los trastornos mentalesm(DSM-5).
    4. El diagnóstico inicial de esquizofrenia debe haberse hecho, como mínimo, 1 año antes de la selección.
    5. El participante está recibiendo actualmente un tratamiento estable de medicamentos psicotrópicos.
    6. El participante presenta una sintomatología estable ≥3 meses antes de la visita de selección.
    7. El participante debe tener un informante adulto.
    8. Un peso corporal de al menos 45 kg y un índice de masa corporal (IMC) de entre 18,0 y 45,0 kg/m2.
    E.4Principal exclusion criteria
    1. Pregnant or breastfeeding or plans to become pregnant during the study.
    2. Exhibit more than a minimal level of extrapyramidal signs/symptoms.
    3. Schizophrenia diagnosis occurred before 12 years of age.
    4. Lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive-compulsive disorder.
    5. Recent occurrence of panic disorder, depressive episode, or other comorbid psychiatric conditions.
    6. Considered by the investigator to be at imminent risk of suicide or injury
    to self, others, or property, or the subject has attempted suicide within 6 months before screening.
    7. Diagnosis of moderate or severe substance use disorder (with the exception of nicotine dependence) within 12 months prior to screening.
    8. Positive drug screen for disallowed substances
    9. Any other medical or psychiatric condition or cognitive impairment that may interfere with study conduct or clinical assessments.
    1. Estar embarazada, en periodo de lactancia o tener previsto quedarse embarazada durante el estudio.
    2. Mostrar más de un nivel mínimo de signos/síntomas extrapiramidales.
    3. El diagnóstico de esquizofrenia se produjo antes de los 12 años de edad.
    4. Diagnóstico de trastorno esquizoafectivo, diagnóstico de trastorno bipolar o diagnóstico de trastorno obsesivo-compulsivo de por vida.
    5. Trastorno de pánico, episodio depresivo u otras afecciones psiquiátricas concomitantes recientes.
    6. El investigador considera que tiene un riesgo inminente de suicidio o de autolesiones, de lesionar a otras personas o dañar bienes, o que ha presentado un comportamiento suicida en los 6 meses anteriores a la selección.
    7. Diagnóstico de trastorno moderado o grave por uso de sustancias (con la excepción de la dependencia a la nicotina) en los 12 meses anteriores a la selección.
    8. Detección de drogas positiva para sustancias no permitidas.
    9. Cualquier otra afección médica o psiquiátrica o deterioro cognitivo que pueda interferir con la realización del estudio o las evaluaciones clínicas.
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline on the Brief Assessment of Cognition in Schizophrenia (BAC) composite score.
    Variación con respecto al valor inicial en la puntuación compuesta de la evaluación breve de la cognición en la esquizofrenia (BACS).
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline to Day 98.
    Valor inicial hasta el día 98.
    E.5.2Secondary end point(s)
    - Change from baseline on the Schizophrenia Cognition Rating Scale (SCoRS) interviewer score.
    - Change from baseline on the Continuous Performance Test-Identical Pairs (CPT-IP) test.
    - Change from baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R) test.
    - Change from baseline on the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT).
    - Change from baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT).
    - Change from baseline on the Clinical Global Impression-Severity Scale (CGI-S) score.
    - Variación con respecto al valor inicial en la puntuación del entrevistador de la escala de evaluación cognitiva en esquizofrenia (SCoRS).
    - Variación con respecto al valor inicial en la prueba de rendimiento continuo, versión pares idénticos (CPT-IP).
    - Variación con respecto al valor inicial en la prueba breve de memoria visuoespacial revisada (BVMT-R).
    - Variación con respecto al valor inicial en la prueba de inteligencia emocional de Mayer-Salovey-Caruso (MSCEIT).
    - Variación con respecto al valor inicial en la herramienta de evaluación para la medición de la capacidad funcional con realidad virtual (VRFCAT).
    - Variación con respecto al valor inicial en la puntuación de la escala de impresión clínica global de la gravedad (CGI-S).
    E.5.2.1Timepoint(s) of evaluation of this end point
    Baseline to Day 98.
    Valor inicial hasta el día 98.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Estudio aleatorizado, doble ciego, comparativo con placebo, seguido de un tratamiento abierto
    A Randomized, Double-Blind, Placebo-Controlled, Followed by Open-Label Treatment
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Mexico
    United States
    Bulgaria
    Spain
    Czechia
    Serbia
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Patient Last Visit
    Último paciente Última visita
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 308
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 95
    F.4.2.2In the whole clinical trial 308
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Normal treatment as discussed with their doctor.
    Tratamiento normal según lo hablado con su médico.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2023-02-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2023-02-10
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 11:42:20 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA